Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 289, Issue 4 58-4, 2005, Pages

  Tallant, E Ann ^a   Ferrario, Carlos M ^a   Gallagher, Patricia E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac hypertrophy; Mitogen activated protein kinases

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7] RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7][D ALA 7]; ANTISENSE OLIGONUCLEOTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR AGONIST; G PROTEIN COUPLED RECEPTOR; LEUCINE; MAS RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RECEPTOR ANTIBODY; THYMIDINE; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; DNA SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; GROWTH INHIBITION; HEART HYPERTROPHY; HEART INFARCTION; HEART MUSCLE CELL; HEART VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; HORMONE ACTION; MYOFIBROBLAST; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; SERUM; WESTERN BLOTTING;

ANGIOTENSIN I; ANIMALS; ANIMALS, NEWBORN; ANTIHYPERTENSIVE AGENTS; CELL DIVISION; CELLS, CULTURED; MAP KINASE SIGNALING SYSTEM; MYOCYTES, CARDIAC; OLIGONUCLEOTIDES, ANTISENSE; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; RNA, MESSENGER; VENTRICULAR REMODELING;

EID: 25444473110     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00941.2004     Document Type: Article

References (54)

1. Aoki H, Richmond M, Izumo S, and Sadoshima J. Specific role of the extracellular signal-regulated kinase pathway in angiotensin II-induced cardiac hypertrophy in vitro. Biochem J 347: 275-284, 2000.
2. Averill DB, Ishiyama Y, Chappell MC, and Ferrario CM. Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation 108: 2141-2146, 2003.
3. Benter IF, Diz DI, and Ferrario CM. Cardiovascular actions of angiotensin-(1-7). Peptides 14: 679-684, 1993.
4. Benter IF, Ferrario CM, Morris M, and Diz DI. Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 269: H313-H319, 1995.
5. Britto RR, Santos RAS, Fagundes-Moura CR, Khosla MC, and Campangnole-Santos MJ. Role of angiotensin-(1-7) in modulation of the baroreflex in renovascular hypertensive rats. Hypertension 30: 549-556, 1997.
6. Brosnihan KB, Li P, and Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 27: 523-528, 1996.
7. Bueno OF, de Windt LJ, Lim HW, Tymitz KM, Witt SA, Kimball TR, and Molkentin JD. The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo. Circ Res 88: 88-96, 2001.
8. Bueno OF, de Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, Hewett TE, Jones SP, Lefer DJ, Peng CF, Kitsis RN, and Molkentin JD. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 19: 6341-6350, 2000.
9. Bueno OF and Molkentin JD. Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res 91: 776-781, 2002.
10. Campbell DJ, Kladis A, and Duncan AM. Nephrectomy, converting enzyme inhibition, and angiotensin peptides. Hypertension 22: 513-522, 1993.
11. DelliPizzi A, Hilchey SD, and Bell-Quilley CP. Natriuretic action of angiotensin(1-7). Br J Pharmacol 111: 1-3, 1994.
12. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, and Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87: E1-E9, 2000.
13. Dostal DE and Baker KM. Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart. Am J Hypertens 2: 276-280, 1992.
14. Ferrario CM. Does angiotensin-(1-7) contribute to cardiac adaptation and preservation of endothelial function in heart failure? Circulation 105: 1523-1525, 2002.
15. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, and Diz DI. Counterregulatory actions of angiotensin-(1-7). Hypertension 30: 535-541, 1997.
16. Fontes MAP, Silva LCS, Campagnole-Santos MJ, Khosla MC, Guertzenstein PG, and Santos RAS. Evidence that angiotensin-(1-7) plays a role in the central control of blood pressure at the ventro-lateral medulla acting through specific receptors. Brain Res 665: 175-180, 1994.
17. Freeman EJ, Chisolm GM, Ferrario CM, and Tallant EA. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 28: 104-108, 1996.
18. Fuller SJ, Davies EL, Gillespie-Brown J, Sun H, and Tonks NK. Mitogen-activated protein kinase phosphatase 1 inhibits the stimulation of gene expression by hypertrophic agonists in cardiac myocytes. Biochem J 323: 313-319, 1997.
19. Garcia NH and Garvin JL. Angiotensin 1-7 has a biphasic effect on fluid absorption in the proximal straight tubule. J Am Soc Nephrol 5: 1133-1138, 1994.
20. Gillespie-Brown J, Fuller SB, Bogoyevitch MA, Cowley S, and Sugden PH. The mitogen-activated protein kinase kinase MEK1 stimulates a pattern of gene expression typical of the hypertrophie phenotype in rat ventricular cardiomyocytes. J Biol Chem 270: 28092-28096, 1995.
21. Glennon PE, Kaddoura S, Sale EM, Sale GJ, Fuller SJ, and Sugden PH. Depletion of mitogen-activated protein kinase using an antisense oligodeoxynucleotide approach downregulates the phenylephrine-induced hypertrophic response in rat cardiac myocytes. Circ Res 78: 954-961, 1996.
22. Handa RK, Ferrario CM, and Strandhoy JW. Renal actions of angiotensin-(1-7) in vivo and in vitro studies. Am J Physiol Renal Fluid Electrolyte Physiol 270: F141-F147, 1996.
23. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, and Ferrario CM. Up-regulation of angiotensin converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 43: 1-7, 2004.
24. Iyer SN, Chappell MC, Averill DB, Diz DI, and Ferrario CM. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with Iisinopril and losartan. Hypertension 31: 699-705, 1998.
25. Iyer SN, Ferrario CM, and Chappell CM. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 31: 356-361, 1998.
26. Jaiswal N, Jaiswal RK, Tallant EA, Diz DI, and Ferrario CM. Alterations in prostaglandin production in spontaneously hypertensive rat smooth muscle cells. Hypertension 21: 900-905, 1993.
27. Jaiswal N, Tallant EA, Jaiswal RK, Diz DI, and Ferrario CM. Differential regulation of prostaglandin synthesis by angiotensin peptides in porcine aortic smooth muscle cells: subtypes of angiotensin receptors involved. J Pharmacol Exp Ther 265: 664-673, 1993.
28. Kohara K, Brosnihan KB, Chappell MC, Khosla MC, and Ferrario CM. Angiotensin-(1-7). A member of circulating angiotensin peptides. Hypertension 17: 131-138, 1991.
29. Liang F, Lu S, and Gardner DG. Endothelin-dependent and -independent components of strain-activated brain natriuretic peptide gene transcription require extracellular signal regulated kinase and p38 mitogen-activated protein kinase. Hypertension 35: 188-192, 2000.
30. Loot AE, Roks AJ, Henning RH, Tio RA, Suurmeijer AJ, Boomsma F, and Van Gilst WH. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 105: 1548-1550, 2002.
31. Lowry OH, Rosebrough MJ, Farr AL, and Randall RJ. Protein measurement with the Folin-phenol reagent. J Biol Chem 193: 265-275, 1951.
32. Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB, and Ferrario CM. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens 14: 799-805, 1996.
33. Nakamoto H, Ferrario CM, Fuller SB, Robaczwski DL, Winicov E, and Dean RH. Angiotensin-(1-7) and nitric oxide interaction in renovascular hypertension. Hypertension 25: 796-802, 1995.
34. Osei SY, Ahima RS, Minkes RK, Weaver JP, Khosla MC, and Kadowitz PJ. Differential responses to angiotensin-(1-7) in the feline mesenteric and hindquarters vascular beds. Eur J Pharmacol 234: 35-42, 1993.
35. Porsti I, Bara AT, Busse R, and Hecker M. Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br J Pharmacol 111: 652-654, 1994.
36. Rockman HA, Wachhorst SP, Mao L, and Ross J Jr. ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. Am J Physiol Heart Circ Physiol 266: H2463-H2475, 1994.
37. 1 receptor subtype. Circ Res 73: 413-423, 1993.
38. Santos RA, Brum JM, Brosnihan KB, and Ferrario CM. The renin-angiotensin system during acute myocardial ischemia in dogs. Hypertension 15, Suppl 2: I121-I127, 1990.
39. Santos RAS, Campagnole-Santos MJ, Baracho NCV, Fontes MAP, Silva LCS, Neves LAA, Oliveira DR, Caligiorne SM, Rodrigues ARV, Gropen C Jr, Carvalho WS, Simoes E, Silva AC, and Khosla MC. Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors. Brain Res Bull 35: 293-298, 1994.
40. Santos RAS, Simoes e Silva AC, Maric C, Silva DMR, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SVB, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, and Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor mas. Proc Natl Acad Sci USA 100: 8258-8263, 2003.
41. Segar JL, Dalshaug GB, Bedell KA, Smith OM, and Scholz TD. Angiotensin II in cardiac pressure-overload hypertrophy in fetal sheep. Am J Physiol Regul Integr Comp Physiol 281: R2037-R2047, 2001.
42. Strawn WB, Ferrario CM, and Tallant EA. Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 33: 207-211, 1999.
43. Sugden PH. Signalling pathways in cardiac myocyte hypertrophy. Ann Med 33: 611-622, 2001.
44. Tallant EA, Diz DI, and Ferrario CM. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle. Hypertension 34: 950-957, 1999.
45. Tallant EA and Ferrario CM. Biology of angiotensin II receptor inhibition with a focus on losartan: a new drug for the treatment of hypertension. Exp Opin Invest Drugs 5: 1201-1214, 1996.
46. Tallant EA, Chappell CM, Ferrario CM, and Gallagher PE. Inhibition of MAP kinase activity by angiotensin-(1-7) in vascular smooth muscle cells is mediated by the mas receptor (Abstract). Hypertension 43: 1348, 2004.
47. Tallant EA and Clark MA. Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension 42: 574-579, 2003.
48. Tallant EA, Diz DI, and Ferrario CM. State-of-the-art lecture. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle. Hypertension 34: 950-957, 1999.
49. Tallant EA, Diz DI, Khosla MC, and Ferrario CM. Identification and regulation of angiotensin II receptor subtypes on NG108-15 cells. Hypertension 17: 1135-1143, 1991.
50. Kip1 signaling pathways (Abstract). Hypertension 40: 403, 2003.
51. Ueyama T, Kawashima S, Sakoda S, Rikitake Y, Ishida T, Kawai M, Yamashita T, Ishido S, Hotta H, and Yokoyama M. Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy. J Mol Cell Cardiol 32: 947-960, 2000.
52. Wei CC, Ferrario CM, Brosnihan KB, Farrell DM, Bradley WE, Jaffa AA, and Dell'Italia LJ. Angiotensin peptides modulate bradykinin levels in the interstitium of the dog heart in vivo. J Pharmacol Exp Ther 300: 324-329, 2002.
53. Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR, and Canver CC. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. Circulation 108: 1707-1712, 2003.
54. Zisman LS, Meixell GE, Bristow MR, and Canver CC. Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate. Circulation 108: 1679-1681, 2003.